NASDAQ:INNT - Innovate Biopharmaceuticals Stock Price, Forecast & News

Innovate Biopharmaceuticals' stock was trading at $0.4715 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INNT shares have increased by 1.8% and is now trading at $0.48. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Innovate Biopharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Innovate Biopharmaceuticals.

Innovate Biopharmaceuticals is scheduled to release its next quarterly earnings announcement on Friday, May 8th 2020. View our earnings forecast for Innovate Biopharmaceuticals.

Innovate Biopharmaceuticals Inc (NASDAQ:INNT) announced its quarterly earnings results on Monday, March, 18th. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11). View Innovate Biopharmaceuticals' earnings history.

Media stories about INNT stock have trended very positive recently, according to InfoTrie. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Innovate Biopharmaceuticals earned a coverage optimism score of 4.0 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the company's share price in the next several days. View the latest news aboutInnovate Biopharmaceuticals.

Innovate Biopharmaceuticals saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 2,243,800 shares, an increase of 7.9% from the February 27th total of 2,080,000 shares. Based on an average trading volume of 215,300 shares, the days-to-cover ratio is presently 10.4 days. Approximately 7.9% of the shares of the company are short sold. View Innovate Biopharmaceuticals' Current Options Chain.

Some companies that are related to Innovate Biopharmaceuticals include SUMMIT THERAPEU/S (SMMT), Cyclerion Therapeutics (CYCN), Clearside Biomedical (CLSD), Genprex (GNPX), SCYNEXIS (SCYX), Monopar Therapeutics (MNPR), Adamas Pharmaceuticals (ADMS), Aldeyra Therapeutics (ALDX), Catabasis Pharmaceuticals (CATB), Galmed Pharmaceuticals (GLMD), Immunic (IMUX), Akorn (AKRX), Aquestive Therapeutics (AQST), Arbutus Biopharma (ABUS) and CTI BioPharma (CTIC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Innovate Biopharmaceuticals investors own include NIO (NIO), Corbus Pharmaceuticals (CRBP), AcelRx Pharmaceuticals (ACRX), Axsome Therapeutics (AXSM), Iterum Therapeutics (ITRM), Momo (MOMO), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Sorrento Therapeutics (SRNE).

Innovate Biopharmaceuticals trades on the NASDAQ under the ticker symbol "INNT."

Shares of INNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INNT stock can currently be purchased for approximately $0.48.

Innovate Biopharmaceuticals has a market capitalization of $19.84 million. The company earns $-27,050,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. Innovate Biopharmaceuticals employs 8 workers across the globe. View additional information about Innovate Biopharmaceuticals.

The official website for Innovate Biopharmaceuticals is http://www.innovatebiopharma.com/.

Innovate Biopharmaceuticals' mailing address is 8480 HONEYCUTT ROAD SUITE 120, RALEIGH NC, 27615. The company can be reached via phone at 919-275-1933 or via email at [email protected]